Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Status:
Completed
Trial end date:
2020-05-27
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design
that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high
risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once
daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborators:
Cleveland Clinic Coordinating Center for Clinical Research (C5R) IQVIA RDS Inc. Quintiles, Inc. The Cleveland Clinic